Physician profile
Ruby May Morant
NPI 1699431916
$1,468.23
in general payments reported to CMS, 2019-2025
13 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $658 · 2023: $631 · 2024: $54.39 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $335.46 | 2022-2023 | Emgality, Jardiance, Mounjaro |
| Abbvie INC. | $326.09 | 2022-2024 | |
| Glaxosmithkline, LLC. | $133.38 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.98 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals Lp | $114.29 | 2022-2023 | Breztri, Farxiga |
| Novo Nordisk INC | $86.13 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.05 | 2022-2023 | Jardiance, Tradjenta |
| Corcept Therapeutics | $76.58 | 2022-2023 | Korlym |
| Pfizer INC. | $72.11 | 2023 | |
| Merck Sharp & Dohme LLC | $57.32 | 2022-2023 | Vaxneuvance, Gardasil 9 |
| Exact Sciences Corporation | $22.65 | 2023 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $19.09 | 2022 | |
| Amgen INC. | $16.10 | 2023 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Morant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.